NCT07400965Phase 2Recruiting

Evaluation of the Safety and Efficacy of GLK-321 in Subjects With Demodex Blepharitis

Study sponsor: Glaukos Corporation

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-09Estimated
Enrollment · participants250Estimated
Source updated2026-02-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.